No Data
[Brokerage Focus] Bank of America Securities upgraded BEIGENE (06160) to a "Buy" rating, indicating strong sales growth of its Bruton tyrosine kinase inhibitors in the United States.
Golden Finance News | Bank of America Securities released a research report indicating that due to the strong sales growth of Brukinsa (small molecule inhibitor of Bruton's tyrosine kinase (BTK)) in the USA, it has raised its revenue forecast, overall adjusting BEIGENE's (06160) revenue forecast from 2023 to 2027 by 6%, 11.8%, and 15.5% respectively. The firm also adjusted its R&D and administrative expenses due to the expansion of the company's product and project portfolio. They stated that the company provided guidance for the full year, with revenue growth expected to range from 29% to 39%, and indicated that operating income and cash flow from operating activities for this year are positive.
BeiGene, Ltd. Files Amended Annual Report With SEC
BeiGene, Ltd. Announces Board of Directors and Committee Roles
Why BeiGene, Ltd. (ONC) Is Skyrocketing So Far in 2025
BeiGene, Ltd. (NASDAQ:ONC) Just Reported And Analysts Have Been Lifting Their Price Targets
US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results
